|
Synonyms: AGEN-1181 | AGEN1181
Compound class:
Antibody
Comment: Botensilimab (AGEN-11810) is a Fc-enhanced anti-CTLA-4 monoclonal antibody [5]. It is proposed as an immuno-oncology agent for the treatment of poorly immunogenic and treatment refractory cancers [4,8]. Heavy and light chain peptide sequences for botensilimab are claimed in patent US10912831B1 [9], nominally SEQ IDs 25 and 27 respectively, and these are the chains of clone AGEN1884.H3 therein.
|
| No information available. |
Summary of Clinical Use ![]() |
| Botensilimab (AGEN-11810) is being investigated in combination with other anti-cancer drugs in advanced solid tumours, with a focus on dual treatment with the anti-PD-1 checkpoint inhibitor balstilimab [2,6-7,10]. |
| Clinical Trials | |||||
| Clinical Trial ID | Title | Type | Source | Comment | References |
| NCT06346197 | Combination of Immune Checkpoint in Locally Advanced or Metastatic MSI/dMMR Esogastric Adenocarcinomas | Phase 3 Interventional | Centre Leon Berard | ||
| NCT06279130 | Pan-tumor Neoadjuvant Basket Study of Immune Check-point Inhibition and Novel Immuno-oncology Combinations | Phase 2/Phase 3 Interventional | The Netherlands Cancer Institute | ||
| NCT06322108 | Assessment of the Safety and Efficacy of Balstilimab in Combination With Botensilimab for the Treatment of Non-Small Cell Lung Cancer (IMMONC0008) | Phase 2 Interventional | Immune Oncology Research Institute | ||
| NCT03860272 | Fc-Engineered Anti-CTLA-4 Monoclonal Antibody in Advanced Cancer | Phase 1 Interventional | Agenus Inc. | 3 | |
| NCT07152821 | Botensilimab + Balstilimab vs Best Supportive Care as Therapy in Chemo-refractory, Unresectable, Colorectal Adenocarcinoma | Phase 3 Interventional | Canadian Cancer Trials Group | The BATTMAN study was terminated in mid-2026 as the developer changed focus away from microsatellite stable metastatic colorectal cancer and towards microsatellite stable colon cancer. | |